AstraZeneca announces breakthrough in breast cancer treatment drug.

On June 1st, AstraZeneca updated information on the effectiveness of its breast cancer drug Camizestrant, with results considered groundbreaking, showing a more than 50% reduction in the risk of tumor growth.

VietnamPlus•02/06/2025

According to the Vietnam News Agency correspondent in the UK, AstraZeneca updated information on June 1st regarding the effectiveness of its breast cancer drug Camizestrant, with results considered groundbreaking.

Information released by the British-Swedish pharmaceutical company at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, shows that this drug, currently in late-stage trials, has demonstrated effectiveness in reducing the risk of tumor growth or death by more than 50% in breast cancer patients.

A global study conducted by AstraZeneca in collaboration with the London Cancer Research Institute, the NHS Royal Marsden Trust, and the Curie Institute in Paris (France) showed that patients with advanced-stage breast cancer who were hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) and treated with Camizestrant in combination with a CDK4/6 inhibitor had a 56% reduced risk of cancer progression.

During the testing of the new drug, an improved blood test method, called liquid biopsy or circulating tumor DNA (ctDNA), was used to detect tumor DNA and identify patients at high risk for tumor mutations before tumors could be detected on scanners. This test allowed patients to be treated with the new drug at an earlier stage.

You may also like

Walking every day but still high blood sugar? 2 ways to lower blood sugar more effectively than walking.GĐXH - Many people believe that simply walking regularly every day is enough to control blood sugar. However, recent studies show that walking at a normal intensity only has limited effectiveness. Two other forms of exercise are the "key" to improving insulin sensitivity and stabilizing blood sugar better.

Bach Mai Hospital's Ninh Binh branch is ready to examine more than 2,000 patients per day.After years of preparation, people can now receive medical examinations and treatment at Bach Mai Hospital's Ninh Binh facility. The new facility is expected to alleviate the burden on the hospital in Hanoi and expand access to specialized medical care for the region.

Universal health insurance - the foundation for sustainable social security.When illness strikes, many people worry not only about the disease itself but also about the cost of treatment. For millions of people, the health insurance card has become a crucial support system, providing peace of mind during treatment, reducing financial burdens, and facilitating access to quality healthcare services. After nearly 17 years of implementing the Health Insurance Law, this policy has increasingly affirmed its role as one of the pillars of the social security system, contributing to the goal of universal healthcare.

According to AstraZeneca, the experimental drug Camizestrant prevented estrogen from binding to cancer cells and destroyed the cells' receptors, making them less resistant to treatment.

The results showed that in patients using the new drug in combination with existing treatment, disease progression slowed by an average of 16 months, compared to 9.2 months in the group using only existing treatment. The trial also found that treatment with the new drug resulted in a significantly longer-lasting quality of life for patients compared to current standards.

In the UK, around 55,000 women are diagnosed with breast cancer each year, and 11,500 die from it, with approximately 70% of patients having HR+ or HER2- breast cancer.
Experts expect this finding could open up new treatment strategies for patients with this common type of cancer. The findings from the trial were published simultaneously in the New England Journal of Medicine.

AstraZeneca currently has nine cancer drugs approved for 37 different types and stages of cancer. With the success of the Camizestrant trial, the British-Swedish pharmaceutical group estimates the new treatment could generate an additional $5 billion in revenue during its peak year.

United States - Vietnam: Don't miss

Vietnam encourages US businesses to expand investment in high technology.On the morning of June 26th, at the Government Headquarters, Deputy Prime Minister Ho Quoc Dung received Mr. Jeff Place, Supply Chain Director of Coherent Group (USA). During the meeting, the Deputy Prime Minister affirmed that Vietnam encourages US businesses to expand investment, especially in high-tech, innovation, and semiconductor industries.

Encourage U.S. businesses to expand investment in high-tech sectors.Deputy Prime Minister Ho Quoc Dung said that Vietnam welcomes US businesses to continue expanding their operations in Vietnam, especially in high-tech industries and sectors with high added value.